Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

The drug in question is sozinibercept, an inhibitor of vascular endothelial growth factors (VEGFs) C and D. Atea had been evaluating a 2-mg dose of sozinibercept every four or eight weeks in ...

Opthia could owe its investors more than $1bn following the results of its Phase III Combination OPT-302 with Aflibercept Study (COAST) trial (NCT04757636), which evaluated its sozinibercept ...

Opthea is scrapping development of lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD, following the failure of another late-stage study. Opthea on Monday ...

(RTTNews) - Opthea Limited (OPT, OPT.AX) announced its decision to discontinue the development of sozinibercept for wet age-related macular degeneration or wet AMD. This follows the negative ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

The global ShORe Phase 3 trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 0.5 mg ranibizumab every four weeks ...

Register for free now. The trial evaluated the efficacy and safety of intravitreally administered 2 mg sozinibercept every four or eight weeks in combination with 2 mg Regeneron Pharmaceuticals ...

Perspective from Rishi P. Singh, MD Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release. After the March 24 release of ...